| __timestamp | Alkermes plc | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 199905000 | 91733000 |
| Thursday, January 1, 2015 | 311558000 | 87644000 |
| Friday, January 1, 2016 | 374130000 | 92365000 |
| Sunday, January 1, 2017 | 421578000 | 85656000 |
| Monday, January 1, 2018 | 526408000 | 88196000 |
| Tuesday, January 1, 2019 | 599449000 | 89971000 |
| Wednesday, January 1, 2020 | 538827000 | 93413000 |
| Friday, January 1, 2021 | 560977000 | 91355000 |
| Saturday, January 1, 2022 | 605747000 | 113676000 |
| Sunday, January 1, 2023 | 689751000 | 198366000 |
| Monday, January 1, 2024 | 645238000 | 218935000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Alkermes plc and Taro Pharmaceutical Industries Ltd. over the past decade. From 2014 to 2023, Alkermes plc has consistently outpaced Taro in SG&A spending, with a notable increase of approximately 245% from 2014 to 2023. In contrast, Taro's SG&A expenses grew by about 140% during the same period.
The data reveals a significant surge in Alkermes' expenses in 2023, reaching a peak, while Taro's expenses also saw a substantial rise. This trend highlights the strategic investments and operational costs that these companies are undertaking to maintain their competitive edge. However, the absence of data for Alkermes in 2024 suggests a potential shift or anomaly worth further investigation.
Breaking Down SG&A Expenses: Johnson & Johnson vs Alkermes plc
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Alkermes plc
SG&A Efficiency Analysis: Comparing Cytokinetics, Incorporated and Alkermes plc
Alkermes plc and MorphoSys AG: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alkermes plc vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: Alkermes plc vs Evotec SE Trends and Insights
Breaking Down SG&A Expenses: Axsome Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.
CRISPR Therapeutics AG or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: PTC Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd. Trends and Insights
Who Optimizes SG&A Costs Better? MorphoSys AG or Taro Pharmaceutical Industries Ltd.
Vericel Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Mesoblast Limited vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends